AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
Erica Hansen(Agios Pharmaceuticals (United States)), Katharine Yen(Agios Pharmaceuticals (United States)), Hua Yang(China Pharmaceutical University), Camelia Gliser(Agios Pharmaceuticals (United States)), Marion Dorsch(Biogen (United States)), Stéphane de Botton(Université Paris-Saclay), Janeta Popovici-Müller(Agios Pharmaceuticals (United States)), René M. Lemieux(Agios Pharmaceuticals (United States)), Kim Straley(Agios Pharmaceuticals (United States)), Jean‐Baptiste Micol(Université Paris-Saclay), Hossein Sadrzadeh(Boston University), Cyril Quivoron(Inserm), Olivier Bernard(Université de Poitiers), Sam Agresta(Agios Pharmaceuticals (United States)), Muriel D. David(Inserm), Virginie Penard‐Lacronique(Université Paris-Sud), Michael Su(First Affiliated Hospital of Henan University), Véronique Saada(Université Paris-Saclay), Amir T. Fathi(University of Southern California)
Cited by 49
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543